Document is current
Any future updates will be listed below
-
Authors
Khunti, Kamlesh https://orcid.org/0000-0003-2343-7099
Banerjee, Amitava https://orcid.org/0000-0001-8741-3411
Evans, Rachael A. https://orcid.org/0000-0002-1667-868X
Calvert, Melanie https://orcid.org/0000-0002-1856-837X
- License Information
-
More Information
Article History
First Online: 25 June 2024
Competing interests
: K.K. was chair of the ethnicity subgroup of the UK Scientific Advisory Group for Emergencies (SAGE), and has acted as a consultant, speaker or received grants for investigator-initiated studies from Astra Zeneca and Pfizer. A.B. has acted as a consultant or speaker for Astra Zeneca, Pfizer and Shionogi and investigator-initiated studies from Astra Zeneca. M.C. has received funding from the UK National Institute for Health and Care Research (NIHR), UK Research and Innovation (UKRI), Macmillan Cancer Support, UCB Pharma, Janssen, GSK, Gilead Sciences, European Commission, European Federation of Pharmaceutical Industries and Associations, and the Brain Tumour Charity; personal fees from Aparito, CIS Oncology, Halfloop, Takeda Pharmaceuticals, Merck, Daiichi Sankyo, Glaukos, GSK, the Patient-Centered Outcomes Research Institute, Genentech and Vertex Pharmaceuticals outside the submitted work; in addition, a family member owns shares in GSK. M.C. is codeveloper of the ‘Symptom Burden Questionnaire for Long COVID’. K.K. (chair), A.B. R.A.E. and M.C. are members of the National Long Covid Research Group that informs the chief medical officer for England.
